Astellas pays Sutro Bio $90M to partner on cancer drugs that make cold tumors hot

Business and Finance

Astellas Pharma already has a piece of the market for antibody drug conjugates (ADCs), a type of cancer therapy that has seen a surge in progress in recent years. The Japanese pharmaceutical giant co-developed Padcev, which has approvals in bladder cancer, under a partnership with U.S. biotech Seagen. Astellas wants to take the targeted approach of ADCs a step further and to do that it’s partnering with another U.S. company. The new alliance with Sutro Biopharma is focused on using that biotech’s technology to develop ADCs with an extra anti-cancer punch.

medcitynews.com     Jun 29, 2022